January 1, 1998Progress in Pediatric CardiologyOpen Access

The prevention of anthracycline cardiomyopathy

View Full Paper

Ask AI

Bookmark

Why the study?

What are the current strategies for the prevention of anthracycline-induced cardiomyopathy?

Population

Patients receiving anthracyclines for solid tumors and leukemias, with a special focus on children

Design

Review

Authors

LSLaurel J. SteinherzPediatrics and Genetics LWLeonard H. WexlerMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Requires ongoing cardiac surveillance in survivors; leaves open development of fully protective strategies.

Structured PICO

What are the current strategies for the prevention of anthracycline-induced cardiomyopathy?

Population

Patients receiving anthracyclines for solid tumors and leukemias, with a special focus on children

Intervention

Strategies to prevent cardiotoxicity including dose limitation, monitoring, altered administration methods, liposomal encapsulation, anthracycline analogues, and cardioprotective agents (e.g., intracellular iron chelators)

Outcome

Prevention of anthracycline-induced cardiotoxicity (acute myopericarditis, subacute cardiomyopathy, and late chronic cardiomyopathy)safety

Current strategies to prevent anthracycline-induced cardiomyopathy are partially effective, highlighting the need for further research and long-term monitoring of cancer survivors.

Cite This Study

Steinherz et al. (1998) studied this question.

synapsesocial.com/papers/6a701ed4e36a167817e1db25 https://doi.org/10.1016/s1058-9813(98)00006-x

View Full Paper

Ask AI

Bookmark

The prevention of anthracycline cardiomyopathy

Discussion

Member takes

Implication

Structured PICO

Cite This Study

The prevention of anthracycline cardiomyopathy

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider